CD274 and triple-negative breast carcinoma: Treatment for triple-negative breast cancer then includes the PD-L1 inhibitor Tecentriq and the PD-1 inhibitor Keytruda, as well as the PARP inhibitors Lynparza and Talzenna (96–98).